AU
UK
CA
NZ
IND
US
Last update at 2026-06-03T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Sidoti Events, LLC's Year-End Virtual Investor Conference
Tue 09 Dec 25, 05:48 PMIridex Announces Preliminary Operational and Financial Results for the First Quarter 2025
Mon 14 Apr 25, 08:05 PMIridex to Host Strategic Vision Call on April 16, 2025
Wed 09 Apr 25, 08:05 PMIridex Reports Fourth Quarter and Full Year 2024 Financial Results
Thu 27 Mar 25, 08:05 PMIridex Announces Strategic Investment in the Company
Wed 19 Mar 25, 01:15 PMIridex Comments on Recent Stock Price Volatility
Fri 14 Mar 25, 11:00 AMIridex to Report Fourth Quarter and Full Year 2024 Financial Results on March 27, 2025
Thu 13 Mar 25, 09:00 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -7.48200M | -5.18500M | -6.30300M | -8.76500M | -12.77600M |
| Minority interest | - | - | - | - | - |
| Net income | -7.54700M | -5.22500M | -6.32900M | -8.81300M | -12.81300M |
| Selling general administrative | 7.56M | 8.86M | 6.62M | 8.38M | 9.55M |
| Selling and marketing expenses | 18.18M | 14.64M | 12.24M | 14.85M | 16.78M |
| Gross profit | 25.37M | 22.83M | 15.56M | 17.94M | 17.47M |
| Reconciled depreciation | 1.38M | 0.80M | 0.50M | 0.69M | 0.81M |
| Ebit | -8.92600M | -8.33600M | -7.08700M | -9.66200M | -13.67700M |
| Ebitda | -7.54200M | -7.53300M | -6.58300M | -8.97400M | -12.86800M |
| Depreciation and amortization | 1.38M | 0.80M | 0.50M | 0.69M | 0.81M |
| Non operating income net other | - | - | 0.28M | 0.21M | 0.09M |
| Operating income | -7.54200M | -7.53300M | -6.58300M | -8.97400M | -12.86800M |
| Other operating expenses | 64.51M | 61.44M | 42.93M | 52.42M | 55.47M |
| Interest expense | 1.44M | 3.15M | 0.78M | 0.90M | 0.00000M |
| Tax provision | 0.07M | 0.04M | 0.03M | 0.05M | 0.04M |
| Interest income | - | - | - | - | - |
| Net interest income | - | - | - | - | - |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.07M | 0.04M | 0.03M | 0.05M | 0.04M |
| Total revenue | 56.97M | 53.90M | 36.35M | 43.45M | 42.60M |
| Total operating expenses | 32.91M | 30.36M | 22.14M | 26.91M | 30.34M |
| Cost of revenue | 31.60M | 31.07M | 20.79M | 25.51M | 25.13M |
| Total other income expense net | 0.06M | 2.35M | 0.28M | 0.21M | 0.09M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -7.54700M | -5.22500M | -6.32900M | -8.81300M | -12.81300M |
| Net income applicable to common shares | -7.54700M | -5.22500M | -6.32900M | -8.81300M | -12.81300M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 34.44M | 42.29M | 48.69M | 27.97M | 34.81M |
| Intangible assets | 1.64M | 1.98M | 2.21M | 0.07M | 0.08M |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.86M | 1.47M | 1.07M | 0.73M | 0.40M |
| Total liab | 24.91M | 25.06M | 25.39M | 10.60M | 12.11M |
| Total stockholder equity | 9.52M | 17.23M | 23.30M | 17.37M | 22.70M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 5.08M | 5.13M | 5.96M | 3.94M | 4.32M |
| Common stock | 0.17M | 0.17M | 0.17M | 0.15M | 0.15M |
| Capital stock | 0.17M | 0.17M | 0.17M | 0.15M | 0.15M |
| Retained earnings | -79.04200M | -69.71600M | -62.16900M | -56.94400M | -50.61500M |
| Other liab | - | 11.87M | 11.01M | 0.39M | 0.54M |
| Good will | 0.96M | 0.96M | 0.96M | 0.53M | 0.53M |
| Other assets | - | 1.46M | 0.27M | 1.56M | 0.15M |
| Cash | 7.03M | 13.92M | 23.85M | 11.63M | 12.65M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 12.97M | 12.45M | 12.65M | 8.68M | 9.78M |
| Current deferred revenue | 2.40M | 2.41M | 2.35M | 0.94M | 1.45M |
| Net debt | -4.28800M | -12.15300M | -21.19600M | -7.43800M | -9.44400M |
| Short term debt | 0.99M | 1.04M | 0.93M | 2.66M | 1.41M |
| Short long term debt | - | - | - | 1.25M | - |
| Short long term debt total | 2.75M | 1.77M | 2.66M | 4.19M | 3.21M |
| Other stockholder equity | 88.44M | 86.80M | 85.25M | 74.18M | 73.09M |
| Property plant equipment | - | 2.13M | 2.99M | 1.88M | 0.73M |
| Total current assets | 27.45M | 35.77M | 42.25M | 25.36M | 30.55M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 14.29M | 20.13M | 16.77M | 22.09M |
| Short term investments | - | - | - | - | - |
| Net receivables | 9.65M | 9.77M | 9.72M | 7.29M | 9.32M |
| Long term debt | - | - | - | 1.25M | - |
| Inventory | 9.91M | 10.61M | 7.61M | 5.71M | 8.17M |
| Accounts payable | 4.50M | 3.87M | 3.40M | 1.15M | 2.59M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -0.05200M | -0.02400M | 0.04M | -0.01900M | 0.08M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 0.15M | 0.15M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | -56.94400M | -50.61500M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 1.40M | 1.46M | 0.27M | 0.13M | 0.15M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 6.99M | 6.52M | 6.43M | 2.61M | 4.26M |
| Capital lease obligations | 2.75M | 1.77M | 2.66M | 1.69M | 3.21M |
| Long term debt total | - | - | - | 1.25M | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -0.28600M | -5.55600M | -0.09300M | -0.50900M | -0.82700M |
| Change to liabilities | 1.95M | 13.68M | -2.02800M | -1.23700M | 1.99M |
| Total cashflows from investing activities | -0.28600M | -5.55600M | -0.09300M | -0.50900M | -0.82700M |
| Net borrowings | - | - | 2.50M | 2.50M | 2.50M |
| Total cash from financing activities | -0.07300M | 9.47M | 2.47M | -0.15600M | 10.38M |
| Change to operating activities | -4.29500M | -1.12200M | -0.94400M | -1.50000M | 0.23M |
| Net income | -7.54700M | -5.22500M | -6.32900M | -8.81300M | -12.81300M |
| Change in cash | -9.93000M | 12.23M | -1.02700M | -8.54100M | -0.51300M |
| Begin period cash flow | 23.85M | 11.63M | 12.65M | 21.19M | 21.71M |
| End period cash flow | 13.92M | 23.85M | 11.63M | 12.65M | 21.19M |
| Total cash from operating activities | -9.51900M | 8.22M | -3.23700M | -7.91300M | -10.02500M |
| Issuance of capital stock | 0.00000M | 9.88M | - | 0.00000M | 10.47M |
| Depreciation | 1.38M | 0.80M | 0.50M | 0.69M | 0.81M |
| Other cashflows from investing activities | - | - | 0.00400M | -0.38100M | -0.38700M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -3.01900M | 0.27M | 2.38M | 0.55M | 0.46M |
| Change to account receivables | 0.20M | 0.64M | 1.86M | -0.27100M | -1.15900M |
| Sale purchase of stock | - | - | - | - | 10.57M |
| Other cashflows from financing activities | -9.95100M | -0.41200M | 2.47M | -0.15600M | -0.09600M |
| Change to netincome | 1.81M | -0.82900M | 1.32M | 1.78M | 1.96M |
| Capital expenditures | 0.29M | 0.21M | 0.10M | 0.13M | 0.44M |
| Change receivables | - | - | 1.86M | -0.27100M | -1.15900M |
| Cash flows other operating | - | - | -1.35500M | -0.60200M | -1.27300M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | -0.86300M | -8.57800M | -0.47300M |
| Change in working capital | -5.16400M | 13.47M | 1.27M | -1.56500M | 0.02M |
| Stock based compensation | 1.62M | 1.63M | 1.12M | 1.70M | 1.80M |
| Other non cash items | 0.19M | -2.45700M | 0.20M | 0.05M | 0.15M |
| Free cash flow | -9.80500M | 8.00M | -3.33400M | -8.04100M | -10.46500M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| IRIX IRIDEX Corporation |
-0.02 1.71% | 1.15 | - | - | 0.88 | 4.87 | 0.81 | -5.2705 |
| ABT Abbott Laboratories |
0.02 0.02% | 86.99 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| SYK Stryker Corporation |
1.70 0.58% | 295.00 | 44.07 | 24.94 | 5.51 | 6.12 | 6.05 | 25.73 |
| MDT Medtronic PLC |
4.20 5.69% | 77.95 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| BSX Boston Scientific Corp |
0.01 0.02% | 47.69 | 31.49 | 17.24 | 4.41 | 3.65 | 4.88 | 19.19 |
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
1212 Terra Bella Avenue, Mountain View, CA, United States, 94043
| Name | Title | Year Born |
|---|---|---|
| Mr. David I. Bruce | Pres, CEO & Director | 1959 |
| Mr. Fuad Ahmad | Interim Chief Financial Officer | 1970 |
| Mr. Patrick Mercer | Chief Operating Officer | 1972 |
| Ms. Leigh Salvo | Head of Investor Relations | NA |
| Mr. David I. Bruce | President, CEO & Director | 1959 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...